Please try another search
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Steven I. Sherman | - | - | Member of Clinical Advisory Board |
Marc A. Stapley | 53 | 2021 | CEO & Director |
Robert S. Epstein | 68 | 2015 | Independent Chair |
Evan Jones | 66 | 2008 | Independent Director |
Edison Tak-Bun Liu | - | - | Member of Scientific Advisory Board |
Karin Eastham | 74 | 2012 | Independent Director |
John L. Bishop | 78 | 2014 | Lead Independent Director |
Jens H. Holstein | 60 | 2020 | Independent Director |
Muna Bhanji | 60 | 2021 | Independent Director |
Eliav Barr | - | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review